To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Acute myeloid leukemia (AML) is a group of clonal malignancies of the bone marrow and peripheral blood. Advances in our understanding of the genetic abnormalities responsible for the development of AML together with the rapidly evolving development of therapeutics that specifically target the underlying genetic lesions have necessitated further refinements in the classification of AML. This is reflected in the recently published International Consensus Classification of AML in which genetically based categorization of AMLs is incorporated to a greater extent than in previous World Health Organization classification schemes, with the goals of improving diagnostic precision, providing more meaningful prognostic information and identifying those patients for whom targeted therapeutics may be beneficial. Genetically defined AMLs account for a higher percentage of cases in children than in adults, and some AML subtypes occur solely in children. This chapter provides an overview of childhood AML, with an emphasis on those entities that are more common or restricted to the pediatric population. Discussion of each AML subtype includes a summary of the molecular pathogenesis and description of the relevant clinical, laboratory, pathologic, and molecular diagnostic features, with an emphasis on differential diagnosis and appropriate utilization of ancillary testing during the diagnostic workup of pediatric AML.
This chapter discusses the diverse immunophenotypic features of acute myeloid leukemia (AML) with mutated TP53. It also addresses immunophenotypic shifts that may occur over the course of the disease.
This chapter covers the detailed immunophenotype of AML with DEK::NUP214 fusion. Different immunophenotypic subtypes (myeloid, myelomonocytic, and monocytic) are discussed. We focus on CD34-positive myeloblasts and describe the expression status and intensity of key markers.
This chapter covers the immunophenotypic features of acute myeloid leukemia (AML) with NPM1 mutation, the most common subtype of AML. In contrast, AML with NPM1 translocation is very rare but is also discussed. Preleukemic cells and clonal hematopoiesis are relatively common in AML with NPM1 mutation, and their distinction from residual AML is critical and highlighted. Other differential diagnosis includes the distinction between cases with an APL (acute promyelocytic leukemia)-like immunophenotype and real APL cases. Occasionally, AML with NPM1 mutation presents with less than 20% blasts and needs to be distinguished from other myeloid neoplasms such as myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia.
This chapter describes the immunophenotype of acute myeloid leukemia (AML) with MECOM rearrangement in detail. Although MECOM rearrangement is predominantly identified in AML, it occasionally occurs in mixed-phenotype acute leukemia (MPAL). Both the immunophenotypes of AML and MPAL associated with MECOM rearrangement are discussed.
This chapter covers the immunophenotype of acute myeloid leukemia (AML) with RUNX1::RUNX1T1. In addition to RUNX1T1, rare cases have RUNX1T3 as the fusion partner with RUNX1, and their immunophenotype is also described. The major differential diagnosis is mixed-phenotype acute leukemia and the distinction is highlighted.
This chapter introduces the classification of acute myeloid leukemia (AML) and highlights the importance of integrating both genetic and immunophenotypic findings in the diagnostic process. AML blasts exhibit a diverse range of immunophenotypic profiles, and key markers associated with each immunophenotypic subtype are discussed. The assessment of minimal residual disease (MRD) is crucial in AML, as it provides important information regarding treatment response and prognosis. Both flow cytometry and molecular testing are used in MRD evaluation.
This chapter describes the diverse immunophenotypic features of AML with NUP98 rearrangement. The fusion partners for NUP98 are diverse, and accordingly, the immunophenotype differs depending on the specific partner involved. Immunophenotypic shift is relatively common in AML with NUP98 rearrangement. Rare cases with a mixed immunophenotype are present.
This chapter evaluates anti-money laundering (AML) regulation of crypto-assets in the UK with a focus on the UK implementation of the EU’s 5th Money Laundering Directive. The UK implementation had a broader scope than that required under the Directive; however, there was a lack of specific requirements and guidance on certain potentially higher-risk areas including privacy coins, mixers, and decentralised finance (DeFi). This chapter suggests that specific AML requirements and guidance on these potentially higher risk areas may help ensure the associated risks are effectively mitigated.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.